Sun, 20 Jul 2008 21:08:31 BST CiteULike: dudamma library [6 articles] http://www.citeulike.org/user/dudamma CiteULike.org en-gb Copyright © 2004-2008 citeulike.org http://www.citeulike.org/user/dudamma/article/2629127 <i></i> Novel Quantitative Biosystem for Modeling Physiological Fluid Shear Stress on Cells 2008-04-04T09:27:30-00:00 bacteria shear stress http://www.citeulike.org/user/dudamma/article/2623750 <i></i> Developmental roles of heparan sulfate proteoglycans: a comparative review in Drosophila, mouse and human 2008-04-02T15:29:23-00:00 hspg http://www.citeulike.org/user/dudamma/article/818080 <i>Nature Reviews Immunology, Vol. 6, No. 9. (18 August 2006), pp. 633-643.</i> The role of heparan sulphate in inflammation Christopher Parish doi:10.1038/nri1918 Nature Reviews Immunology, Vol. 6, No. 9. (18 August 2006), pp. 633-643. 2006-08-26T10:53:03-00:00 2006 Nature Reviews Immunology 1474-1733 6 9 633 643 Nature Publishing Group hspg inflammation http://www.citeulike.org/user/dudamma/article/2623620 <i>Annual Review of Biochemistry, Vol. 68, No. 1. (1999), pp. 729-777.</i><br /><br />Abstract The heparan sulfate on the surface of all adherent cells modulates the actions of a large number of extracellular ligands. Members of both cell surface heparan sulfate proteoglycan families, the transmembrane syndecans and the glycosylphosphoinositide-linked glypicans, bind these ligands and enhance formation of their receptor-signaling complexes. These heparan sulfate proteoglycans also immobilize and regulate the turnover of ligands that act at the cell surface. The extracellular domains of these proteoglycans can be shed from the cell surface, generating soluble heparan sulfate proteoglycans that can inhibit interactions at the cell surface. Recent analyses of genetic defects in Drosophila melanogaster, mice, and humans confirm most of these activities in vivo and identify additional processes that involve cell surface heparan sulfate proteoglycans. This chapter focuses on the mechanisms underlying these activities and on the cellular functions that they regulate. FUNCTIONS OF CELL SURFACE HEPARAN SULFATE PROTEOGLYCANS Merton Bernfield Martin Gotte Pyong Park Ofer Reizes Marilyn Fitzgerald John Lincecum Masahiro Zako doi:10.1146/annurev.biochem.68.1.729 Annual Review of Biochemistry, Vol. 68, No. 1. (1999), pp. 729-777. 2008-04-02T14:44:47-00:00 1999 Annual Review of Biochemistry 68 1 729 777 hspg http://www.citeulike.org/user/dudamma/article/1364758 <i>Int. J. Dev. Biol., Vol. 46 (2002), pp. 267-278.</i> Developmental roles of heparan sulfate proteoglycans: a comparative review in Drosophila, mouse and human Marc Princivalle Ariane de Agostini Int. J. Dev. Biol., Vol. 46 (2002), pp. 267-278. 2007-06-04T21:53:35-00:00 2002 Int. J. Dev. Biol. 46 267 278 composition ivig preparations http://www.citeulike.org/user/dudamma/article/2606320 <i>Journal of Neurology, Vol. 253, No. 0. (2006), pp. v18-v24.</i><br /><br />Abstract   The original rationale for the therapeutic application of immunoglobulins was prevention and treatment of infectious diseases. With the description of agammaglobulinemia, substitution therapy became the primary indication for the use of immunoglobulins. Limitations and side effects of the intramuscular administration of immunoglobulins led to the development of preparations for intravenous use (IVIg). In the early 1980s an immunomodulatory effect of IVIg was described. Since then, the efficacy of IVIg has been established in controlled trials for diseases like idiopathic thrombocytopenic purpura, Kawasaki disease, Guillain-Barré syndrome, dermatomyositis, and many others. There is a large body of evidence that IVIg can modulate an immune reaction at the level of T cells, B cells, and macrophages, interferes with antibody production and degradation, modulates the complement cascade, and has effects on the cytokine network. However, the precise mechanism of action is not yet clear. Basic principles of intravenous immunoglobulin (IVIg) treatment Martin Stangel Refik Pul doi:10.1007/s00415-006-5003-1 Journal of Neurology, Vol. 253, No. 0. (2006), pp. v18-v24. 2008-03-28T13:18:16-00:00 2006 Journal of Neurology 253 0 v18 v24 ivig